WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ASH2025--Incyte Announces More than 50 Abstracts Accepted for Presentation at the 2025 ASH Annual Meeting. ...

公司概况 - 公司是医疗-生物医学和遗传学行业的知名企业 [1] - 公司以创新疗法闻名，尤其在肿瘤学领域 [1] - 旗舰产品Jakafi是治疗血癌的主要疗法，对公司收入贡献显著 [1] - 公司与制药行业其他主要参与者竞争，通过持续研发维持市场地位 [1] 财务表现 - 2025年第三季度每股收益为2.26美元，超出Zacks共识预期1.66美元 [2] - 2025年第三季度收益超出预期36.14% [2] - 2025年第三季度营收为13.7亿美元，超出Zacks共识预期8.71% [2] - 2025年第三季度营收高于去年同期的11.4亿美元 [3] - 公司过去四个季度营收持续超出预期 [3] - Jakafi的强劲需求是增长关键驱动因素，公司已上调该药物年度销售预测 [3] 股价与市场表现 - 当前股价为89.66美元，下跌2.17%，变动1.99美元 [4] - 当日股价在88.34美元低点和94.42美元高点之间波动 [4] - 过去一年股价最高达94.42美元，最低为53.56美元 [4] - 公司市值约为175亿美元 [4] - 当日交易量为597,177股 [4] 分析师观点与公司事件 - RBC Capital于2025年10月29日设定目标价为84美元，当时股价为91.65美元 [2] - 该目标价暗示潜在下行风险约为8.35% [2] - 公司2025年第三季度营收和收益均超出预期，主要受Jakafi强劲需求推动 [5]

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-12400 INCYTE CORPORATION (Exact name of registrant as specified in its charter) (State or other jurisdict ...

财务业绩 - 第三季度总收入为13.7亿美元，同比增长20%，超出市场预期的12.6亿美元 [1] - 调整后每股收益为2.26美元，较去年同期的1.07美元大幅增长，超出市场预期的1.66美元 [2] - 总产品净收入为11.5亿美元，同比增长19% [1] 产品收入表现 - Jakafi产品净收入增长7%至7.91亿美元 [4] - Opzelura产品净收入增长35%至1.88亿美元 [4] - Minjuvi/Monjuvi产品净收入跃升34%至4199万美元 [4] - 新上市产品Niktimvo净收入增长27%至4600万美元，自2025年第一季度推出后需求强劲 [5] 研发与产品管线 - 公司正积极审查研发工作，专注于具有科学差异性、能满足未竟医疗需求且能推动下一阶段增长的高价值项目 [3] - 基于管线优先排序，已暂停INCA034460、INCB57643项目以及povorcitinib在慢性自发性荨麻疹适应症的开发 [4] 业绩指引 - 公司上调2025财年产品净收入指引至42.3亿至43.2亿美元，主要受Jakafi及其他血液学和肿瘤学产品需求推动 [6] - Jakafi的2025年产品净收入指引从30亿至30.5亿美元上调至30.8亿美元 [6] - 其他肿瘤学产品净收入指引上调至5.5亿至5.75亿美元，此前为5亿至5.2亿美元 [6] - Opzelura的销售指引维持在6.3亿至6.7亿美元不变 [7] 市场表现与行业观点 - Jakafi的稳定增长持续带来稳健现金流，但其2028年专利独占权到期仍是投资者的关键担忧 [7] - Escient资产的临床挫折以及povorcitinib在化脓性汗腺炎适应症的弱效结果限制了公司新产品驱动增长的前景 [7] - 公司股价报92.69美元，接近其52周高点93.17美元 [8]

Incyte (INCY) reported a breakout quarter on Oct. 28, beating Wall Street’s revenue and earnings estimates. Best known for its blockbuster drug Jakafi and expanding oncology pipeline, this biotech combines profitability, pipeline depth, and long-term growth potential while trading under $100. Valued at $18.2 billion, Incyte stock is up 31.9% year-to-date, outperforming the broader market gain of 17.3%. Should you grab this biotech stock now? More News from Barchart www.barchart.com About Incyte Incyte ...

Incyte Corporation (NASDAQ:INCY) is one of the most profitable biotech stocks to buy. Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Incyte Corporation (NASDAQ:INCY) on October 22, setting a price target of $104. However, J.P. Morgan analyst Jessica Fye reiterated a Hold rating on Incyte Corporation (NASDAQ:INCY) on October 20. Incyte Corporation (INCY): Among Small-Cap Healthcare Stocks Hedge Funds is Buying Fye associated the rating with the company’s market position and cur ...

Key Takeaways Incyte's Q3 adjusted EPS of $2.26 beat estimates and more than doubled year over year.Revenues rose 20% to $1.37B, fueled by Jakafi and strong Opzelura demand in the U.S. market.New drugs Zynyz, Minjuvi, and Niktimvo posted robust sales, further boosting overall performance.Incyte Corporation (INCY) reported third-quarter 2025 adjusted earnings of $2.26 per share, which beat the Zacks Consensus Estimate of $1.66. The company had incurred adjusted earnings of $1.07 per share in the year-ago qua ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

财务业绩概览 - 公司2025年第三季度营收达13.7亿美元，同比增长20.1% [1] - 季度每股收益为2.26美元，较去年同期的1.07美元大幅提升 [1] - 营收和每股收益均超市场预期，营收惊喜度为+8.71%，每股收益惊喜度为+36.14% [1] 细分收入表现 - 产品总收入为11.5亿美元，超出分析师平均预估的10.9亿美元，同比增长19.4% [4] - 产品特许权使用费收入为1.7112亿美元，超出1.6443亿美元的平均预估，同比增长9.1% [4] - 旗舰产品Jakafi收入为7.9107亿美元，超出7.6999亿美元的平均预估，同比增长6.7% [4] - 关键增长产品Opzelura收入为1.8797亿美元，超出1.7913亿美元的平均预估，同比增长35% [4] - 产品Zynyz表现突出，收入2267万美元远超946万美元的平均预估，同比大幅增长3167.2% [4] 各产品线业绩 - Iclusig收入3758万美元，超出3063万美元的平均预估，同比增长26.4% [4] - Pemazyre收入2274万美元，略高于2199万美元的平均预估，同比增长10.1% [4] - Minjuvi/Monjuvi收入4199万美元，超出3787万美元的平均预估，同比增长33.6% [4] - Niktimvo收入4583万美元，高于4268万美元的七位分析师平均预估 [4] - 特许权收入中Olumiant为3711万美元，与3717万美元的预估基本持平，同比增长6.7% [4] - Tabrecta特许权收入651万美元，低于715万美元的平均预估，但同比增长9.9% [4] - Jakavi特许权收入1.2565亿美元，超出1.1918亿美元的平均预估，同比增长8.6% [4] 市场表现与展望 - 公司股价在过去一个月内上涨11%，表现优于同期Zacks S&P 500指数3.6%的涨幅 [3] - 公司目前Zacks评级为3级（持有），预示其近期表现可能与整体市场同步 [3]